Leukemia cells prevent immune system from clearing tumor cells by inducing the
immunosuppression of the bone marrow (BM) microenvironment. In recent years, further …

Over the past several years, advances in research, treatment, and market dynamics have
impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They …

Imatinib Mesylate (imatinib) was once hailed as the magic bullet for chronic myeloid
leukemia (CML) and remains a front-line therapy for CML to this day alongside other …

Angiogenic growth factors (AGFs) are a class of secreted cytokines related to angiogenesis
that mainly include vascular endothelial growth factors (VEGFs), stromal-derived factor-1 …

Background Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term
therapy with high efficacy and safety. Asciminib, a BCR:: ABL1 inhibitor specifically targeting …

The study initially determined the baseline inhibitory concentration (BIC) for ASC
monotherapy and each ABPI using the K562/WT and BaF3/WT cell lines, respectively …

Simple Summary Chronic myeloid leukemia is a type of blood cancer that is regarded as a
success story in determining the exact biological origin, pathogenesis and development of a …

With cancer being a leading cause of death globally, there is an urgent need to improve
therapeutic strategies and identify effective chemotherapeutics. This study aims to highlight …

Ponatinib is a third‐generation BCR:: ABL1 tyrosine kinase inhibitor (TKI) with high potency
against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated …

Because genetic alterations including mutations, overexpression, translocations, and
dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this …